The G 1 /S checkpoint of the cell cycle is regulated by p16, p53 and RB tumor suppressor genes. Loss of expression of the p16 INK4 tumor suppressor protein, the product of the CDKN2 gene, has been associated with a wide variety of human malignancies. Mutations, loss of heterozygosity and deletions o
Does p16ink4a expression increase with the number of cell doublings in normal and malignant lymphocytes?
β Scribed by Amel Chebel; Wei-Wen Chien; Luc-Marie Gerland; Yahia Mekki; Yves Bertrand; Patrick Ffrench; Carlos Maria Galmarini; Martine Ffrench
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 627 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Vascular endothelial growth factor (VEGF) expression has been suggested to correlate with intratumoral microvessel density, tumor advancement and prognosis in esophageal squamous cell carcinoma (ESCC). Previous studies have showed that disruption of cell cycle regulator p16 is related t
## Abstract Loss of p16^INK4a^ protein expression has frequently been related to DNA methylation in association with gene silencing. Although the methylation status of exon1Ξ± for p16^INK4a^ involvement in various cancers has been extensively analyzed, it has been pointed out that some inconsistenci
The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alte
Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16 INK4A (p16). Most benign tumours showed no p16 expression in the tumour